Participated · Series A · Aug 2024

Power to Hydrogen develops AEM (anion exchange membrane) electrolysis technology that converts renewable electricity and water into high‑pressure hydrogen using earth‑abundant materials. Its core product enables high current density and high‑pressure green hydrogen production while meeting industry durability requirements. The company is completing development of an industrial‑scale electrolysis stack and system for what it calls the largest AEM electrolysis stack installment in the world. Funding will support global expansion of R&D, manufacturing, sales, and marketing and growth of its U.S. team in Columbus, Ohio, plus new offices in Belgium. Rev1 Ventures and corporate partner Worthington Enterprises are backing the company, and Rev1 provides strategic services and customer collaborations alongside capital. To date Power to Hydrogen has secured over $18MM in total funding to advance commercialization of its technology.

Participated · Series A · Nov 2022

Samsara Eco develops and sells fossil-free polymer resins and enzyme-based recycling technology (EosEco) intended to replace fossil fuel–derived plastics in packaging, textiles and other products. The company has built an enzyme library that can recycle polyester, nylon 6 and the more difficult nylon 6,6, and it launched its first product made from enzymatically recycled polyester in partnership with Lululemon. Samsara is constructing facilities in Jerrabomberra, New South Wales to provide partner testing and creation services, and plans additional facilities in Southeast Asia and its first North American facility. It was founded in 2020 in collaboration with the Australian National University, Woolworths and Main Sequence and currently employs about 60 staff across Australia and North America, with plans to expand headcount to 90 by the end of 2025. The company says its EosEco process operates at lower temperature and pressure than conventional recycling and achieves a life-cycle assessment well below the carbon footprint of virgin plastics. Samsara aims to scale to recycling 1.5 million tonnes of plastic per year by 2030 and is targeting expansion into apparel, consumer packaged goods, automotive and electronics sectors. Samsara Eco develops enzyme-based technology that rapidly depolymerizes plastics into their core molecules, enabling repeated recycling. The company launched last year in partnership with the Australian National University and has expanded an enzyme library now capable of depolymerizing several plastic types. It plans to build its first commercial recycling facility in Melbourne later this year, targeting full-scale production by 2023 and claiming the facility will infinitely recycle 20,000 tons of plastic starting in 2024. Initial processing will focus on PET and polyester, and the technology is described as tolerant of contamination and able to handle colored, mixed and multi-layered plastics. Samsara says the new funding will be used to expand its enzyme library, fund the commercial facility, grow its engineering team and expand operations into Europe and North America. The company is preparing to launch enzymatically recycled packaging with Woolworths next year and aims to recycle 1.5 million tons of plastic per year by 2030, with Woolworths committed to turning the first 5,000 tons into branded packaging. Samsara Eco has developed an enzyme-based process that breaks plastics into their molecular building blocks (monomers) for infinite recycling or upcycling. The company says its process achieves full depolymerization in about an hour at room temperature and can be run in a carbon-neutral way, saving an estimated three tonnes of CO2 for every tonne of plastic recycled. Launched in 2021, Samsara has a 13-person team of scientists, engineers and researchers, including collaborators from the Australian National University. It has commercial partnerships with Woolworths Group, which committed to using the first 5,000 tonnes of recycled Samsara plastic in own-brand packaging, and with Tennis Australia to recycle 5,000 bottles. Samsara raised $6 million to build its first recycling plant later this year and expects full-scale production to start in 2023; it is targeting an additional roughly $50 million raise later this year to fund a first commercial-scale facility to recycle 20,000 tonnes per annum. Investors named in the current raise include the Clean Energy Finance Corporation (CEFC), W23 and Main Sequence.

Participated · Series B · Jul 2022

Naluri provides digital employee health and wellbeing services from its base in Singapore. The company has secured a $5 million tranche led by Telus Global Ventures’ Pollinator Fund for Good. Sumitomo Corporation Equity Asia, M Venture Partners and unnamed investors also participated in the raise. The $5 million is part of a broader $14 million Series B round. Proceeds will be used for working capital, market expansion and to support a new commercial partnership. The raise is framed as an expansion-focused round to accelerate the company’s commercial growth. Naluri operates a digital platform (the Naluri app) that pairs evidence-based interventions with human-led clinical expertise to deliver integrated, person-centred care for people at risk of or managing chronic and mental health conditions. The company serves more than 75 of the region’s leading employers across industries including financial services, oil and gas, property development, telecommunications, tertiary education and aviation. Founded in 2017 and based in Malaysia, Naluri currently operates in Malaysia, Singapore, Thailand and Indonesia and has imminent plans to expand into the Philippines, Hong Kong and Australia. Its core offering blends digital tools with coaching and clinical support to prevent and manage pervasive chronic and mental-health conditions. The business recently secured new capital to accelerate regional expansion and bolster operations across existing markets. Leadership emphasizes rapid, effective scaling of prevention and care services to reach more people in the region. Naluri Hidup is a Malaysia-based digital health service provider. The company announced it closed a $5 million Series A funding round. The article does not provide details on the company's specific products or services beyond describing it as a digital health provider. No operating metrics, founding year, or use-of-proceeds information are included in the article. Participating investors and any strategic or financial partners were not disclosed. The article also does not describe the company’s future plans or roadmap. Naluri is a Malaysia-based digital health startup. The company provides digital health services and is eyeing regional expansion. Naluri announced it had closed a $1.5 million pre-Series A funding round. The round was led by German venture capital firm Global Founders Capital. No operating metrics, past rounds, or other investors were disclosed in the report. Naluri Hidup is described in the article as a Malaysia-based digital health startup. The report states the company closed seed financing totaling roughly RM1 million (approximately $258,570). The round was led by Singapore-based healthcare analytics firm BioMark alongside Silicon Valley’s 500 Startups participating via its Southeast Asia-focused fund, 500 Durians. The article does not disclose details about Naluri Hidup’s specific products, services, user metrics, revenue, or financial runway. No information on the company’s future plans, product roadmap, or additional operating metrics was provided in the article. Further company or market details were not included in the sourced text.

Participated · Series A · Dec 2021

Sonic Incytes Medical develops Velacur™, a handheld, point-of-care 3D liver health assessment solution that quantifies liver disease with technology similar to MRI elastography combined with 3D tissue sampling. Velacur is FDA-cleared, non-invasive, delivers results in about five minutes, and was launched in the U.S. market in early 2021. The device is intended to provide consistently accurate, real-time liver diagnostics in a physician’s office as an alternative to biopsy and MRI. Sonic Incytes positions the product as accessible and affordable to enable routine assessment and improved management of chronic liver disease. The company emphasizes reducing fatty liver disease and improving patient care through point-of-care ultrasound diagnostics. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes spun out of the University of British Columbia. Sonic Incytes Medical develops a portable, handheld point-of-care ultrasound solution for assessing and managing chronic liver disease, with a focus on fatty liver disease. The device uses technology similar to MRI elastography and quantifies liver disease using 3D tissue sampling to provide consistently accurate, real-time results. The company says the entire procedure takes about five minutes and offers a quick, safe, and comfortable alternative to biopsy and MRI. Sonic Incytes plans to enter the market at the end of 2020. Financially, it completed a seed financing round of over CDN$3.5 million, including a $1 million investment from Genome BC and over $2.5 million from institutional and angel investors. Founded in 2017 and headquartered in Vancouver, British Columbia, Sonic Incytes aims to commercialize its solution to improve diagnosis, treatment and management of liver disease.